Search PubMed⌕ Search

Biomedical subjects

E Hochuli

Publications and source records attributed to E Hochuli.

At least 37 records · Page 2Linked to original sources
PubMed1987

Specificity of the immunoadsorbent used for large-scale recovery of interferon alpha-2a.

After immunoaffinity chromatography, interferon alpha-2a synthesized in bacteria is not homogeneous. Beside oligomers and monomers, a fragment of molecular weight 15,000 was observed. Amino acid analysis and the determination of the amino terminal amino acid sequence of the fragment indicate that this polypeptide represents an interferon alpha-2a molecule lacking the 22 terminal amino acids. In order to define the epitope on the interferon alpha-2a molecule recognized by the immunoadsorbent, the binding to the immunoadsorbent of interferon alpha-2a fragments prepared by cyanogen bromide cleavage was studied. The results suggest that cyanogen bromide fragments Arg 22-Met 59 and Lys 112-Met 148 are recognized. Since the oligomers, the monomers and the fragment of molecular weight 15,000 of interferon alpha-2a share these sequences, the different forms are as expected co-purified on the immunoadsorbent.

Amino Acid Sequence↗
PubMed1987

[Laparoscopy in gynecology and obstetrics].

Thanks to the statistics of the Arbeitsgemeinschaft Schweizerischer Frauenkliniken (Swiss Gynecological Clinics' Working Group) it has for the first time become possible to report on larger numbers of laparoscopies performed in Switzerland. In contrast to most international statistical records, data relating to this subject are gathered prospectively; there is no doubt that this improves the quality of the data. The authors report on a total of 18,186 laparoscopies performed in 1983/84/85, in 50% of the cases for sterilization. The various sterilization methods employed are discussed. As far as diagnostic laparoscopies are concerned, the indications and techniques are described. Serious intraoperative complications occurred in 15 cases, which corresponds to one serious complication in every 1,212 laparoscopies. Fortunately, not a single patient died as a direct result of the laparoscopy. The results are compared with those in the international literature. With regard to late-onset morbidity it is evident that there are more complications with the more complex procedure of diagnostic laparoscopy.

Female↗
PubMed1987

[Obstetric-gynecologic data collection for quality control and responding to health and political status questions. A survey based on 250,000 patients].

Since January 1, 1983 a total of 250,000 patient records have been stored in computer-compatible form in the data base of the Working Group of Swiss Gynecologic Clinics (59 gynecologic-obstetric departments). The information resulting from this mass of data is commented on and analyzed in concise form. Problems of quality control, health care and status-related policies can be addressed and resolved on the basis of up-to-date data which are always available. In the authors' experience, the benefit of correctly compiled statistics is indisputable.

Cesarean Section↗
PubMed1987

Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity.

Lipstatin, a new and very potent inhibitor of pancreatic lipase (the key enzyme of intestinal fat digestion) was isolated from Streptomyces toxytricini. Lipstatin contains a beta-lactone structure that probably accounts for the irreversible lipase inhibition. The IC50 of lipstatin for pancreatic lipase is 0.14 microM. In mice triolein absorption was dose-dependently inhibited by lipstatin, whereas oleic acid was absorbed normally. Other pancreatic enzymes, such as phospholipase A2 and trypsin, were not inhibited even at an inhibitor concentration of 200 microM.

Animals↗
PubMed1987

Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation.

The structure of a new pancreatic lipase inhibitor, lipstatin, produced by Streptomyces toxytricini was determined as (2S,3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methylpentanoyloxy ]-2-hexyl-3- hydroxy-7,10-hexadecadienoic lactone by spectroscopic and chemical methods. Structurally lipstatin is closely related to the known esterase inhibitor esterastin. It contains a N-formyl-L-leucine side chain instead of the N-acetyl-L-asparagine in esterastin.

Chemical Phenomena↗
PubMed1986

[Severe urge incontinence--therapeutic concept].

Basing on our experience with 39 patients with severe urge incontinence (in one-quarter of the cases pure urge incontinence, in one-half of the cases mixed incontinence and in a further quarter of the cases neurogenic bladder disorders) a supervised programme (mictiogram) and a well-tried therapy (especially in the Anglo-Saxon countries) consisting of the triad hospitalisation/bladder training/medication therapy are presented. After an average hospitalisation period of 14 days, we were able to achieve a symptom-free state in 94% of the patients. Cure was achieved on a long-term basis in 76%. Failure of conservative therapy was due especially to severe neurogenic bladder disorders, followed by urethral obstructive insufficiency that cannot be influenced. The superimposed psychic cause of urge incontinence that should not be underestimated and often presents as a transference of unresolved emotional needs (51% of our group are psychologically unstable), is discussed. With these facts in mind, our therapy concept is translated into reality. Hospitalisation brings about a change in surroundings, making the supervision of bladder training and adjustment to medication easier, thus supplying the basis for patient compliance and success of follow-up therapy subsequent to hospitalisation and discharge from hospital.

Adult↗
PubMed1986

[Gynecologic cancers: preventive examinations and their limits. An analysis of the current staging and percentage distribution based on 2,612 cancers of the 1 January 1983 to 25 November 1985 cumulative statistics of the Society of Swiss Gynecologic Clinics].

An overview of the stages and age distributions is given for 2612 invasive genital and 1237 breast cancer cases, called from the data bank, compiled by the Swiss working group of the departments of gynaecology and obstetrics and consisting of 172,399 cases (1983-1985). The general over-representation of advanced and more therapy-resistant cancer stages (exception: corpus cancer) and their high incidence in advanced menopausal age, still characterise the present, all but satisfactory condition. Progress in the treatment of genital and breast cancers can be achieved only through improved early diagnosis with preventive examinations, without a limitation placed on age.

Breast↗
PubMed1986

Swiss adjuvant trial (OSAKO 06/74) with chlorambucil, methotrexate, and 5-fluorouracil plus BCG in node-negative breast cancer patients: nine-year results.

Between 1974 and 1977, a total of 254 patients with stages T1-3a, N0-1, and M0 operable breast cancer (node negative and node positive, stratified) were randomized to either modified radical mastectomy alone or the same surgery and adjuvant chlorambucil, methotrexate, 5-fluorouracil (LMF) plus BCG. After a median follow-up of 9 years (January 1985), we concluded that LMF plus BCG significantly increased relapse-free survival (RFS) in 240 fully evaluated patients, especially postmenopausal women. This gain in RFS ceased to transform into a gain in overall survival (OAS) after 7 years of median follow-up for the whole patient group. In the 122 node-negative patients studied, LMF plus BCG produced a marked increase in RFS up to the fifth year and in OAS up to 8 years after initial surgery, thus prolonging significantly the median disease-free interval compared with surgical control patients. This trend favoring LMF plus BCG-treated patients continues. Although median time to first relapse and to generalized disease were increased in relapsing patients by LMF plus BCG, the subsequent intervals from local relapse to distant disease and from distant metastases to death were equal for both treatment regimens. Subjective and objective acute toxicity from LMF plus BCG was mild. At 9 years of median follow-up, fewer second tumors were noted in the node-negative group receiving LMF plus BCG than in surgical controls.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1984

[Perioperative and perinatal morbidity and mortality. Pilot study by a working team of Swiss gynecological hospitals].

The article presents joint annual statistics for 1982 as a perioperative and perinatal morbidity and mortality analysis representing a pilot study by the working team of 41 Swiss gynaecological hospitals. This serves as a model for a meaningful quality control programme. The data of 50,770 patients (including 24,656 births) have been stored. The evaluation programmes which can be read off directly supply for every index word on the patient record the median and quartile ranges of the entire data bank and hence the basis of internal control within the hospital.

Delivery, Obstetric↗
PubMed1984

[Cesarean section and risk of infection].

The risk of infection associated with Caesarean section is several times greater than normal parturition. The only way to effectively combat nosocomial infections is to ensure harmonious and well-balanced interplay between general antimicrobial measures at all levels (i.e., hospital hygiene), even though the rate of Caesarean sections has been on the increase, while avoiding at the same time the general use of antibiotics. The article presents a suitable overall concept to prevent infection. This has been successful in reducing the rate of both antibiotics consumption and of infectious complications at our hospital during the past 15 years.

Anti-Bacterial Agents↗